The impact of obesity on the immune response to infection by Milner, J. Justin & Beck, Melinda A.
Micronutrients, immunology and inflammation The impact of 
obesity on the immune response to infection
J. Justin Milner and Melinda A. Beck*
Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at 
Chapel Hill, Chapel Hill, NC, USA
Abstract
There is strong evidence indicating that excess adiposity negatively impacts immune function and 
host defence in obese individuals. This is a review of research findings concerning the impact of 
obesity on the immune response to infection, including a discussion of possible mechanisms. 
Obesity is characterised by a state of low-grade, chronic inflammation in addition to disturbed 
levels of circulating nutrients and metabolic hormones. The impact of these metabolic 
abnormalities on obesity-related comorbidities has undergone intense scrutiny over the past 
decade. However, relatively little is known of how the immune system and host defence are 
influenced by the pro-inflammatory and excess energy milieu of the obese. Epidemiological data 
suggest obese human subjects are at greater risk for nosocomial infections, especially following 
surgery. Additionally, the significance of altered immunity in obese human subjects is emphasised 
by recent studies reporting obesity to be an independent risk factor for increased morbidity and 
mortality following infection with the 2009 pandemic influenza A (H1N1) virus. Rodent models 
offer important insight into how metabolic abnormalities associated with excess body weight can 
impair immunity. However, more research is necessary to understand the specific aspects of 
immunity that are impaired and what factors are contributing to reduced immunocompetence in 
the obese. Additionally, special consideration of how infection in this at-risk population is 
managed is required, given that this population may not respond optimally to antimicrobial drugs 
and vaccination. Obesity impacts millions globally, and greater understanding of its associated 
physiological disturbances is a key public health concern.
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Globally, the number of obese individuals has reached alarming proportions. According to 
the WHO latest estimates, approximately 500 million adults and nearly forty-three million 
children under the age of 5 years are considered to be obese (BMI ≥ 30)(1). Obesity is 
defined as a state of excess adiposity and its cause, although multifactorial, is primarily due 
to prolonged positive energy balance. Several comorbidities are associated with this disease, 
especially immune dysfunction. Alterations in inflammation and immune cell function in the 
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obese play a significant role in nearly all pathophysiological effects of obesity(2,3). However, 
few studies have directly addressed how this may affect host defence. In fact, there is 
striking evidence in both human subjects and mice that a state of excess adiposity greatly 
increases susceptibility to infections. Despite the strong epidemiological evidence in human 
subjects and immunological findings in rodents, much remains to be learned about obesity-
related immune impairment. Furthermore, the mechanisms directly and indirectly 
responsible for differences in immune activity and host defence between healthy weight and 
obese individuals remain unclear.
In addition to an increased research focus on this topic, there may be implications for 
management of infections in the obese. For example, evidence is accumulating that obese 
individuals may respond differently to vaccination and various drugs, such as antibiotics. In 
combination with impaired immunity, altered responses to interventions may further affect 
the outcome of infection. Increased susceptibility to infection has obvious health and 
monetary consequences at the individual level. However, given that one out of every ten 
adults is obese, concerns of rising health care costs and disease transmission become a 
concern for all(1).
Evidence of impaired immunity in obese human subjects
Recent studies have demonstrated altered immune cell function in obese human subjects 
compared with those of healthy-weight. Nieman et al. reported considerable discrepancies in 
leucocyte number and subset counts and phagocytic and oxidative burst activity of 
monocytes between lean and obese individuals(4). Additionally, circulating mononuclear 
cells in the obese exhibit a pro-inflammatory state compared with healthy-weight persons(5). 
Impaired lymphocyte proliferation to polyclonal stimulation has been reported as well(4). 
Type II diabetes, a common complication of obesity, is associated with impaired immune 
cell activity(6). Individuals with a genetic mutation preventing proper synthesis of the 
hormone leptin, become morbidly obese and display weakened immune defences(7). 
Interestingly, obesity has been shown to enhance thymic aging and reduce T-cell repertoire 
diversity, thus possibly impacting immune surveillance(8). The reported findings of immune 
cell dysfunction suggest that obesity may result in impaired host defence. Indeed, studies 
have linked obesity with increased risk of infection(9). Several reports have found obesity to 
be a significant risk factor for post-operative and surgical site(10), nosocomial(11), 
periodontal(12) and respiratory infections(13).
Infections in clinical settings
Obese patients have increased intensive care unit (ICU) length of stay(14) and are more 
likely to die(15–17) in the hospital. Further, several epidemiological investigations have 
reported that obesity increases infection susceptibility in clinical settings(9). Obese patients 
are prone to developing post-operative complications. In fact, numerous studies have 
reported obesity to be an independent risk factor for post-operative infections(18–28). In a 
recent secondary analysis of a large prospective observational study including critically ill 
and injured patients remaining in the ICU for 48 h or more, obesity was reported to be an 
independent risk factor for catheter and blood stream infections(11). A study in critically 
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injured blunt trauma patients reported that morbid obesity (BMI ≥ 40) was associated with 
increased risk of pneumonia and urinary tract infection but not with increased mortality(21).
The impact of obesity on clinical outcomes in hospitalised patients is clearly multifactorial 
and complex. In addition to decreased immunocompetence, there are other potential factors 
that may contribute to increased susceptibility to infection in the hospital setting. For 
example, underlying disease in the obese may inhibit proper mobility in the hospital, which 
can increase risk for skin breakdown(29). Due to inadequate equipment or improperly trained 
staff, obese individuals may have prolonged visits at the hospital, thus increasing risk for 
acquiring nosocomial infections(9,29). Another consideration is that pharmacokinetics of 
antibiotics may differ in the obese, potentially affecting susceptibility to post-operative 
infections(30). Therefore, it is difficult to determine the direct impact of impaired immunity 
on severity of nosocomial infections in obese patients, but accumulating evidence suggests a 
significant role.
Obesity and respiratory infections
A striking number of recent studies have reported obesity to be a predictor for a worse 
outcome of infection with the 2009 influenza A (H1N1) pandemic strain(31). In fact, several 
countries across the world have reported data indicating that obese individuals were 
disproportionately represented among influenza-related hospitalisations and deaths. Obesity 
or morbid obesity increased risk of ICU admission and even death among those infected 
with the pandemic strain(32–35). Those admitted to ICU had a reportedly longer duration of 
mechanical ventilation and increased time in ICU and hospitals compared with non-obese 
individuals(36). Before the advent of the 2009 pandemic season, there were no such reports 
investigating the relationship between obesity and influenza infection in human subjects. 
Recently, however, Kwong et al. published a study that explored the relationship between 
BMI and seasonal influenza infection using a series of Canada’s cross-sectional population-
based health surveys(37). The surveys covered twelve influenza seasons. Analysis of the 
retrospective cohort demonstrated that the obese are at greater risk for respiratory 
hospitalisations during the seasonal flu periods.
In contrast to the recent surge of publications highlighting a connection between influenza 
severity and obesity, there is very little known about obesity and other respiratory tract 
infections(38). A recent study by Akiyama et al. suggests that obesity may impact the 
response to respiratory syncytial virus infection in children(39). A study from Poland 
reported that BMI was significantly related to susceptibility to respiratory infections in 
children(13). In critically ill trauma patients, obesity or morbid obesity was associated with 
respiratory infections(11,15,23). Conversely, a few studies have also reported obese 
individuals are not at greater risk for respiratory infections(14,40). Therefore, our 
understanding of the effect of obesity on risk for pulmonary infection remains unclear. 
However, it is important to consider that obesity can complicate lung mechanics, such as 
restricting lung volume (reviewed in(41)), which could potentially increase risk for 
pneumonia or other infections. Although the mechanisms contributing to increased 
susceptibility may include impaired immunity, there may be non-immune factors to 
consider.
Milner and Beck Page 3













Vaccination and management of infection in the obese
Vaccination is universally recommended by public health officials to combat several types 
of infections. However, there is some evidence suggesting that obese individuals may not 
respond to vaccination to the same extent as healthy-weight individuals. Obesity was 
associated with a poor antibody response to hepatitis B vaccination(42,43). Additionally, 
overweight children displayed considerably lower anti-tetanus IgG antibodies in response to 
vaccination compared with healthy-weight children(44). This reduced immunogenicity in 
response to vaccination could be caused by several factors. One possibility is impaired 
generation and/or function of the antibody-secreting plasma cells. Another factor could be 
reduced absorption of the vaccine at the site of injection due to excess adiposity(44). 
Interestingly, a recent study reported that using a larger vaccine needle length resulted in 
considerably higher antibody titres to hepatitis B surface antigen in obese adolescents(45). As 
mentioned, poor response to vaccination has important public health implications. Reduced 
protection against viral infections, such as hepatitis B, increases individual susceptibility and 
may increase the likelihood of transmission to others. Therefore, more research on how 
obesity may negatively impact vaccination response is necessary to ensure proper protection 
in this at risk population.
In addition to the infections mentioned earlier, increased BMI is associated with greater risk 
for several other bacterial infections including periodontal infections(12), Staphylococcus 
aureus nasal carriage(46) and gastric infection by Helicobacter pylori(47). Also, a recent 
study reported that obesity was significantly associated with herpes simplex virus 1 
infection, which was determined by sero-positivity(48). Despite increased risk for several 
types of microbial infections, there is little known about how obesity may alter the 
pharmacokinetics of antimicrobial drugs (reviewed in(30)). Studies assessing dosing of the 
antibacterial drug, vancomycin, suggest that obese patients may require different dosages(49) 
and different dosing intervals(50) compared with non-obese individuals. An additional study 
of the antimicrobial drug, linezolid, reported diminished serum concentrations in the obese 
compared with healthy-weight volunteers receiving the same dose(51). As pointed out 
previously, there is greater risk of skin breakdown in obese individuals in clinical settings 
due to restricted mobility, improperly sized rooms and equipment and the special challenges 
of caring for patients undergoing or post-bariatric surgery(9,29). Additionally, excess 
adiposity may reduce tissue perfusion and affect wound healing(29). Taken together, it is 
clear that obesity predisposes individuals to nosocomial infections, and that careful 
consideration of infection prevention and treatment is required.
Rodent models of obesity and infection
A limited number of studies have demonstrated the negative impact of excess adiposity on 
immune cell function in rodent models. The implications of these studies, in terms of 
obesity-related immunity impairments, are often complicated by the use of genetic models 
of obesity. The most commonly used genetically altered rodents for this purpose are the 
ob/ob and db/db mice and the rat fa/fa counterpart. These rodent models lacking leptin or the 
leptin receptor are very useful for the study of obesity-related comorbidities, as they display 
metabolic abnormalities characteristic of obesity such as hyperglycaemia, dyslipidaemia, 
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glucocorticoid excess and hyperinsulinaemia(52,53) (all of which could potentially alter 
immune cell homoeostasis and function). However, given the vast amount of research 
highlighting the importance of leptin in immunity(54), a global deficiency in leptin signalling 
makes it difficult to tease apart the mechanisms contributing to impaired immunity and 
greater susceptibility to infections in these genetic models of obesity. Nonetheless, these 
models still provide insight into how excess adiposity may directly or indirectly alter 
immune cell function and host defence against infectious agents.
In general, a deficiency of leptin (ob/ob) or the leptin receptor (db/db) in mice increases 
susceptibility to bacterial infections and pneumonia(38). Using ob/ob mice, Mancuso et al. 
demonstrated that a complete deficiency of leptin resulted in impaired pulmonary clearance 
upon Klebsiella challenge, likely due to defective alveolar mac-rophage and neutrophil 
phagocytosis(55). Similarly, an investigation by Hsu et al. reported that ob/ob mice exhibited 
enhanced lethality and delayed clearance of Streptococcus pneumoniae following a 
pulmonary challenge(56). Interestingly, intraperitoneal injections of leptin prior to 
Streptococcus infection improved survival after the bacterial challenge, but not to the level 
of wild-type mice. This discrepancy in survival percentages may, in fact, be caused by the 
increased adiposity of the ob/ob mice. Other studies have reported that ob/ob mice exhibit 
greater pulmonary Mycobacterium tuberculosis load(57) and delayed clearance of the 
Mycobacterium abcessus(58) upon challenge.
In addition to these pulmonary infection models, mice lacking the leptin receptor were 
shown to be more susceptible to hind paw staphylococcal infection and exhibited a greater 
inflammatory response compared with wild-type mice(59). Furthermore, db/db and ob/ob 
mice displayed impaired resistance to hepatic Listeria monocytogenes infection(60). Obese 
Zucker rats show decreased ability to clear yeast infection upon challenge with Candida 
albicans(61).
It is clear that evidence highlighting the importance of leptin for host defence is rapidly 
accumulating. However, these studies do not offer insight into the mechanisms by which 
excess body fat (and related metabolic abnormalities) may actually hinder host defence. 
Adding exogenous leptin to ob/ob mice is helpful in understanding the impact of other 
metabolic abnormalities on immune dysfunction, but exogenous administration of leptin in 
mice still differs from studying animals with intact leptin production and signalling. Some 
key considerations include indirect effects of leptin on immune responses and the fact that 
leptin has been shown to have autocrine signalling capabilities on select immune cells(62). 
Although infection models in ob/ob or db/db mice provide important information on the role 
of leptin in host defence and immunity, these mice do not properly model non-genetically 
induced obesity, which constitutes the vast majority of human obesity.
Diet-induced obesity (DIO) in rodents more closely mimics human obesity. DIO mice, 
similar to their human counterparts, develop the typical comorbidities associated with 
obesity including elevated leptin, insulin resistance and elevated liver TAG. Although the 
diet models of obesity are often utilised to study metabolic problems associated with 
obesity, fewer studies have utilised these models in the context of an infection.
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Compared with lean control mice, DIO mice have greater morbidity and mortality during 
either a primary or secondary influenza infection(63,64). Several forms of immunity 
impairment were observed in the DIO mice, including reduced natural killer cell activity, 
poor dendritic cell processing and presentation and impaired CD8+ T-cell function(64,65). 
The mechanism(s) for the immune alterations in the DIO mice remains unclear.
An interesting study by Shamshiev et al. reported apoE−/− mice fed a high fat and 
cholesterol diet displayed impaired resistance to Leishmania major infection due to impaired 
dendritic cell function and T-helper type 1 cell immunity(66). Impaired T-cell activity was 
also reported in DIO mice transgenic for a T-cell receptor specific to a peptide derived from 
ovalbumuin(67). One complication associated with using DIO is elucidating whether the 
observed outcome of infection can be attributed to the abundance of adipose tissue, the 
influence of the high-fat diet or both. In this case, utilising both genetic obesity models with 
intact leptin signalling and DIO models in conjunction may be beneficial in advancing our 
understanding of the impact of the diet v. the state of excess adiposity on immunity(68,69). 
Another important aspect of diet studies to consider is use of a proper control diet. A defined 
high-fat diet is commonly used for DIO models, but rarely do investigators include the 
matched control diet that only differs in fat and carbohydrate content(70). In addition to 
major differences in macro- and micronutrient content, phytoestrogens are nearly absent in 
defined high-fat diets, whereas chow has high but variable levels(71). Phytoestrogens can 
have marked effects on rodent physiology including hormone levels, metabolism and 
locomotor activity(72–74). Thus, usage of a chow diet can potentially confound the effects of 
a high-fat diet(70). Careful consideration of diet and experimental design is important in 
assessing the impact of obesity or diet on immunity.
Mechanisms of altered cellular immune function in the obese
It is well known that obesity is associated with a state of chronic, low-grade inflammation 
both in white adipose tissue and systemically(75–78). Additionally, obesity is characterised 
by altered levels of circulating hormones and nutrients such as glucose and lipids. 
Circulating immune cells and those resident in peripheral tissues are thus exposed to an 
energy-rich environment in the context of altered concentrations of metabolic hormones. 
Understanding how this pro-inflammatory, excess energy milieu impacts immune cell 
function is key in understanding the immunodeficient state associated with obesity. 
Although these metabolic abnormalities can undoubtedly have indirect effects on immune 
cells, this review will focus on the direct impact of these abnormalities on immune cells.
Immunomodulatory adipokines and hormones in obesity
The primary adipose derived immunomodulatory adipokines include leptin, adiponectin and 
the proinflammatory cytokines: TNFα, IL-6 and IL-1β(76,77,79). Adiponectin, levels of which 
are decreased during obesity, has been shown to alter natural killer cell cytotoxicity and 
cytokine production by human myeloid cells(80,81). Conversely, there is excess production of 
TNFα, IL-6 and IL-1β in white adipose tissue of the obese(77). These cytokines can be 
secreted into the blood and potentially have distal effects; however, exactly how chronic 
production of these cytokines impacts cellular immunity remains to be elucidated. It is 
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possible that chronic exposure to pro-inflammatory cytokines may desensitise immune cells 
to inflammatory responses during an actual infection(82).
The pleiotropic effects of leptin on immune cell activity are highly diverse and 
complicated(54). Nearly all cells of the innate immune system express the isoform of the 
leptin receptor, obRb, required for leptin signalling(83–87). In monocytes, leptin up-regulates 
pro-inflammatory cytokine production of IL-6, IL-12 and TNFα, as well as phagocytic 
activity(55,88,89). In polymorphonuclear neutrophils of healthy individuals, leptin signalling 
induced chemotaxis, reactive oxygen species generation and influenced oxida-tive 
capacity(87,90,91). Natural killer cells are highly influenced by leptin signalling, including 
aspects of differentiation, proliferation, activation and activity(85,92). Given the importance 
of leptin to innate immune cell function, it follows that nearly all innate immune cells are 
impaired in mice lacking intact leptin signalling.
The adaptive arm of the immune response is equally affected by leptin signalling(83,86). 
Leptin is an important source of pro-survival signals to double-positive and single-positive 
thymocytes during the maturation of T-cells(93). Leptin has been shown to play a key role in 
lymphopoieses and myelopoieses given that ob/ob mice had only 60% as many nucleated 
cells in bone marrow as compared with wild-type controls(94). In the presence of a 
polyclonal stimulator, leptin can increase T-cell proliferation and can modulate expression 
of activation markers on both CD4+ and CD8+ T-cells(95). Leptin can also have profound 
effects on cellular activity by functioning as a regulator of immune cell metabolism(62,96).
Although several papers have discussed how leptin may be required for or may enhance 
immune cell function, few have taken into consideration the fact that obese individuals are 
hyperleptinaemic(97). Therefore, in obese models, we should ask what are the potential 
impacts of excess leptin signalling on immune cells? Indeed, studies have demonstrated that 
T-cells(86) and natural killer cells(98) can become resistant to leptin in rodent models of 
obesity. Leptin signals through a JAK/STAT (Janus kinase/signal transducer and activator of 
transcription) signalling pathway, resulting in translocation of the transcription factor, 
STAT3 (signal transducer and activator of transcription 3), into the nucleus and subsequent 
transcription of leptin-induced genes, including suppressor of cytokine signalling-3(99). 
Suppressor of cytokine signalling 3 functions as a negative feedback mediator of JAK/STAT 
signalling, and thus may play an important role in impairing leptin signalling and 
contributing to central and peripheral leptin resistance(100). Leptin resistance could very well 
explain obesity-related impaired immunity, as this would mimic a state of leptin deficiency. 
Leptin resistance, induced by hyperleptinaemia, would obviously not occur in ob/ob mice, 
which is another reason these mice are not the best model for studying obesity-related 
immune dysfunction. Although it is widely accepted that leptin resistance occurs centrally in 
the hypothalamus(100–102), peripheral leptin resistance requires further investigation.
An additional and somewhat novel consideration is how hyperleptinaemia may impact the 
function and distribution of regulatory T-cells (Treg). An elegant study by De Rosa et al. 
demonstrated a role for leptin signalling in Treg proliferation and function(62). Abrogation of 
leptin signalling alters the anergic state of Treg, and allows for enhanced proliferation. 
Although highly proliferating Treg tend to lose some of their suppressive activity(62), 
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resistance to leptin signalling might contribute to greater Treg number. Treg have the 
capacity to suppress nearly all aspects of the immune response(103). Thus, this hypothesis 
fits with the immunosuppressive phenotype associated with infections in the obese. In fact, a 
recent investigation demonstrated a greater percentage of Treg in the spleen of DIO mice 
despite lower levels in adipose tissue(104). It is clear that obesity can alter Treg number and 
function(104–106), but the extent to which this population of immune cells affects infection 
outcomes in the obese remains unknown.
Hyperinsulinaemia and insulin resistance are common features of obesity; however, there is 
little known regarding the immunomodulatory effects of excess insulin or impaired insulin 
signalling in the context of obesity. How the effects of insulin on cellular immunity are only 
partially understood. Monocytes have been shown to express insulin receptors and are 
insulin sensitive immune cells(107–110). Interestingly, resting T-cells are insulin insensitive 
in that the insulin receptor is absent from the plasma membrane. However, once T-cells are 
activated by a polyclonal stimulator, such as phytohaemagglutinin or by specific antigen, 
effector T-cells up-regulate de novo emergence of insulin receptors(111,112). Insulin 
signalling induces glucose uptake, amino acid transport, lipid metabolism and can modulate 
T-cell activation and function(111,113). Furthermore, insulin promotes an anti-inflammatory 
T-helper type 2 cell phenotype(112), but MacIver et al. speculate that insulin resistance in 
obesity may actually enhance T-helper type 1 cell development(96). It is thus clear that 
insulin can have potent effects on immune cell metabolism and function, but the effects of 
excess insulin on immunity remain relatively unresearched.
Altered immune cell metabolism in an abnormal metabolic environment
Immune cells from both innate and adaptive defences require nutrients such as glucose, 
amino acids and fatty acids to meet energy needs(114). However, energetic demands and 
nutrient preference depend on cell type and cellular activity. For example, once T-cells are 
activated, they become highly proliferative and secretory, and thus require an abundant 
source of energy that will rapidly yield large quantities of ATP(115). Conversely, 
macrophages and neutrophils are generally considered to be non-proliferative and thus have 
a different metabolic profile and nutrient requirements(114,116). Although glucose and fatty 
acids are important sources of energy for host defence and immune function(117), elevated 
levels of these nutrients, as in the obese, may have consequences for immune cell activity.
Glucose uptake by immune cells is facilitated by the family of glucose transport proteins, 
GLUT. A variety of GLUT are expressed on immune cells. For example, increased 
expression of GLUT3 and GLUT5 occurs during the differentiation of monocytes to 
macrophages(118). GLUT1 appears to be the primary GLUT on T-cells, and functions to 
maintain glucose uptake for basic metabolic requirements(96,115). Upon stimulation, GLUT1 
and GLUT3 levels were shown to increase on T-cells and monocytes(118). Glucose is 
required for proper T-cell proliferation and survival(96). However, it has also been shown 
that exposing T-cells to high concentrations of glucose can result in reactive oxygen species 
generation and lipid peroxidation(119). Although little is known of the in vivo effects of 
hyperglycaemia on immune cell function, Jacobs et al. demonstrated that overexpression of 
GLUT1 in mouse T-cells resulted in altered T-cell metabolism and cytokine production(120). 
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The mechanisms by which elevated glucose influence immune cell function are not entirely 
clear, but glucose plays a crucial role in activity of immune cells, and thus excessive levels 
are likely to have a significant impact on cellular function.
Similar to glucose, fatty acids are important in fuelling an immune response, as they are a 
readily available source of abundant energy. However, the impact of excess circulating 
NEFA, a hallmark of obesity(121), on immune cells has not been well studied. Interestingly, 
SFA, such as palmitate, share similarities in chemical structure to lipopolysac-charide. This 
observation sparked studies indicating that SFA can induce an inflammatory response by 
initiating Tolllike receptor (TLR) signalling pathways(122–126). TLR are critical in inducing 
innate immune responses as they recognise conserved molecular patterns on microbial 
pathogens(127). SFA, but not unsaturated, have been shown to activate both TLR2 and TLR4 
resulting in TIR (Toll/IL-1 receptor) domain-containing adaptor-inducing interferon-β-
dependent and myeloid differentiation factor 88-dependent signalling pathways and a 
subsequent inflammatory response(122–128). NEFA have been shown to trigger inflammatory 
responses in both macrophages and dendritic cells indicating that both innate and adaptive 
immune responses can be affected(126,129). The effect of elevated NEFA on insulin 
resistance and type II diabetes has been widely examined(128). Cells of both innate and 
adaptive immunity express TLR2 and TLR4, and other than a small number of studies in 
macrophages(3,129–131), there is very little known of the impact of NEFA on TLR signalling 
in other immune cells, such as T-cells. However, a study by Stentz and Kitabchi reported 
that increasing concentrations of palmitate but not unsaturated fatty acids resulted in 
activation of T-cells and a dose-dependent increase in cyto-kine production as well as 
reactive oxygen species generation and lipid peroxidation in vitro(132).
An additional consideration in which excess fatty acids, as well as glucose and metabolic 
hormones, may affect immunity is highlighted in several recent studies demonstrating that 
T-cell populations can have distinct metabolic programmes that are critical to cell fate and 
function(133). Michalek et al. show that CD4+ T-cell metabolism is fundamental in 
regulating differentiation to an effector or regulatory subtype. The CD4+ T effector subset 
requires glycolytic metabolism, and Treg require lipolytic oxidation(133). Interestingly, 
recent studies have shown that CD8+ effector T-cells displayed a glycolytic phenotype, 
whereas a CD8+ memory T-cell population was associated with a lipid oxidation metabolic 
profile(134–136). What remains to be studied is how nutrition may alter these distinct 
metabolic programmes. In the context of obesity, how do elevated levels of glucose, fatty 
acids and metabolic hormones, such as leptin and insulin, impact the metabolic fate of 
immune cells during an infection?
Conclusion
The best solution to improving health of obese individuals is significant weight loss. 
However, the aetiology of this highly complex disease is multifactorial, and thus no solution 
to obesity will be an easy fix. The burden of obesity is shared by adolescents and adults 
alike, and of the numerous comorbidities associated with obesity, host defence and immune 
cell dysfunction are less studied compared with type II diabetes or cardiovascular 
complications. Obesity clearly interferes with protection against infectious agents, and 
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therefore increased research for a better understanding of the interactions between excess 
adipose-related metabolic abnormalities and immune cell activity is needed. Strong 
epidemiological evidence highlighting an association between obesity and infection is 
accumulating, and there are rodent models offering insight into potential mechanisms. An 
additional, yet key, consideration is how best to prevent and manage infections in this at risk 
population. Antimicrobial drugs and vaccines may not function as intended in obese 
individuals. This is cause for major concern in the context of outbreaks of infection, as for 
the 2009 influenza pandemic. Further consideration and investigation on the impact of 
obesity on immunity could potentially save millions of lives, especially during the current 
obesity epidemic dilemma.
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